Lysosomal α-Galactosidase A 的成熟和对法布里病的影响
Efecan Aral1,2,3, Scott C Garman1,2
1Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, Massachusetts, USA.
Nephron
|June 17, 2025
概括
法布里病是一种遗传性代谢障碍,源于缺少α-银酸酶A活性,导致脂积累. 了解酶成熟是预测疾病结果和开发向治疗的关键.
科学领域:
- 生物化学 生化学
- 遗传学 是一个遗传学.
- 溶酶体储存疾病 溶酶体储存疾病
背景情况:
- 费布里病是一种遗传性代谢障碍,其特征是溶酶体内积聚诸如环球酸胺 (Gb3) 等螺旋脂.
- 这种积累是由于酶α-galactosidase A (α-Gal A) 的活性不足造成的,该酶通常从Gb3.3中分离终端α-galactose糖.
- 已在患者中发现超过1000种不同的突变,突出显示了α-Gal A缺乏症的遗传复杂性.
研究的目的:
- 复杂的分子步骤涉及到适当的合成和成熟的α-galactosidase A酶的审查.
- 阐明这些成熟过程中的缺陷如何导致法布里病的发病.
- 讨论针对患者α-Gal A活性的当前和新兴治疗策略.
主要方法:
- 关于α-galactosidase A生物发生,功能和相关突变的现有文献的综述.
- 在法布里病中分析基因型-表型相关性.
- 检查药理性护卫剂和酶替代疗法的作用机制.
主要成果:
- α-银酸酶A的正确功能取决于精确的多折叠,翻译后修饰,溶酶体贩运和基质结合.
- 在α-Gal A成熟的不同阶段的失败可能导致酶活性降低,随后Gb3积累,导致法布里病.
- 药理伴随剂可以增强某些α-Gal A变体的活性,提供治疗途径.
结论:
- 了解α-galactosidase A的分子旅程对于预测疾病进展和开发有效治疗法布里病至关重要.
- 费布里病的单遗传性质允许基因型-表型相关性,有助于临床管理.
- 向治疗,包括药理伴随者,旨在恢复或增强α-Gal A功能,以减轻疾病病理.
相关概念视频
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:20Inborn Errors of Metabolism
249
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
249